Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06604884 · ClinicalTrials.gov registry record

NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study

A clinical trial of Intracranial Aneurysm, sponsored by Medtronic Neurovascular Clinical Affairs.

Recruiting
Registry status
118
Enrollment target
2
Study locations

NCT06604884 is a study of Intracranial Aneurysm that is actively recruiting participants, run by Medtronic Neurovascular Clinical Affairs. The registered enrollment target is 118 participants, below the 9,188-participant average among 14 other Intracranial Aneurysm trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06604884, a study of Intracranial Aneurysm, is actively recruiting participants, sponsored by Medtronic Neurovascular Clinical Affairs.

RECRUITING
Registry status
118 participants
Enrollment target
2
Study locations

Study Summary

The purpose of the Pipeline™ Vantage Embolization Device with Shield Technology™ Post Approval Study (PAS) ("Pipeline™ Vantage PAS") is to collect safety and effectiveness data in patients undergoing treatment for intracranial aneurysms (IA) using the Pipeline™ Vantage Embolization Device with Shield Technology™ ("Pipeline™ Vantage Device") in a post approval setting.

Conditions Studied

Interventions

  • DEVICE Treatment of Intracranial Aneurysms

Study Locations (2)

Georgia

  • Wellstar Research Institute - Marietta

Michigan

  • McLaren Healthcare - Flint

Trial Details

FieldValue
Enrollment Target 118 participants
Start Date 2025-12-12
Est. Completion 2033-09

What the Registry Record Tells You About NCT06604884

The ClinicalTrials.gov registry entry for NCT06604884 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,188-participant average among 14 other Intracranial Aneurysm trials with a reported enrollment target (99% lower). The listed sponsor is Medtronic Neurovascular Clinical Affairs, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Intracranial Aneurysm appearing as the primary indexed condition, and to 1 intervention - of which Treatment of Intracranial Aneurysms is the first listed.

NCT06604884 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Georgia, Michigan.

Frequently Asked Questions

What is clinical trial NCT06604884 about?

NCT06604884 is a clinical study titled "NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study". The purpose of the Pipeline™ Vantage Embolization Device with Shield Technology™ Post Approval Study (PAS) ("Pipeline™ Vantage PAS") is to collect safety and effectiveness data in patients undergoing treatment for intracranial aneurysms (IA) using the Pipeline™ Vantage Embolization Device with Shiel...

What is the current status of trial NCT06604884?

This trial is currently recruiting. The enrollment target is 118 participants. The study started on 2025-12-12. Estimated completion is 2033-09.

What conditions does trial NCT06604884 study?

This clinical trial studies the following conditions: Intracranial Aneurysm.

What interventions are being tested in trial NCT06604884?

The interventions under investigation include: Treatment of Intracranial Aneurysms (DEVICE).

Who is sponsoring clinical trial NCT06604884?

This trial is sponsored by Medtronic Neurovascular Clinical Affairs, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06604884 being conducted?

This trial has 2 study locations across Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Intracranial Aneurysm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.